T2T strategy in gout lowers cardiovascular risk

A real-world data analysis from English and Swedish healthcare records reveals that a treat-to-target (T2T) approach in urate-lowering therapy (ULT) modestly but significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with gout. “We and others have previously described the associations of gout flares and subsequent cardiovascular events,” said Dr Edoardo Cipolletta (Polytechnic University of Marche, Italy) [1]. His study aimed to evaluate the impact of achieving a serum urate treatment target of <360 μmol/l within the first year of treatment on the 5-year risk of MACE among patients with gout and newly prescribed ULT. The study included 116,518 patients from 2 major European cohorts, the UK CPRD Aurum and Sweden’s VEGA database. Patients were classified into 2 groups: those achieving the serum urate target of <360 µmol/L urate within 12 months of ULT initiation (T2T-ULT) and those who did not (fire-and-forget)....

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 20 June 20258 August 2025